TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00927927
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 0 mg/kg administered subcutaneously (under the skin); cohort 1-7b on day 1, cohort 8-11 biweekly four times
Study: NCT00927927
Drug: NNC0142-0002
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple dose, ranging from 0.02 mg/kg up to max 4.0 mg/kg, administered subcutaneously (under the skin) four times biweekly
Study: NCT03403634
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT02877485
Drug: Ayr saline nasal mist
Normalized name: Ayr Saline Nasal Mist
Approvals — FDA: no, EMA: no, PMDA: no
Description: 110mcg (2 sprays) sprayed to both nostrils daily for 42 days.
Study: NCT00363987
Drug: Ketosteril®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet Ketosteril/5kgBW/d
Study: NCT01181895
Drug: Placebo Inhalation Powder NDPI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo inhalation powder inhaled orally via Novel Dry Powder Inhaler
Study: NCT01181895
Drug: Placebo Inhalation Powder Diskus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo inhalation powder inhaled orally twice daily for 12 weeks
Study: NCT00821691
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo caps
Study: NCT02177344
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01363323
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02066298
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05095480
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo receiving group
Study: NCT04242199
Drug: INCB099280
Approvals — FDA: no, EMA: no, PMDA: no
Description: INCB099280 administered orally in 25 mg or 100 mg tablets once daily or twice daily on each day of each 28-day cycle
Study: NCT02609126
Drug: EP-104IAR
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single, ultrasound-guided injection of EP-104IAR into the knee
Study: NCT02609126
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single, ultrasound-guided injection of vehicle placebo into the knee
Study: NCT01679119
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 750mg/m2 IV, given day 1
Study: NCT01679119
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone 100mg OD Oral given days 1-5
Study: NCT02348489
Drug: SGI-110 (guadecitabine)
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Investigational medicinal product
Study: NCT02348489
Drug: Treatment Choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choice of one: cytarabine, decitabine, or azacitidine
Study: NCT01922596
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00151801
Drug: estroprogestins
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03788889
Drug: Placebo A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injection
Study: NCT03788889
Drug: Placebo B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion
Study: NCT04244474
Drug: A single one ml injection
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: All children were treated with antibiotics according to WHO classification and treatment of childhood pneumonia at health facilities 2012 \[18\], at enrollment after obtaining consent from parents and completing the baseline assessment, children were given a single injection of one ml of 100.000 IU of vitamin D3 (Cholecalciferol), vitamin D3 obtained from 2 ml vials containing 200,000 IU each (Devarol- S- 200.000 I.U. produced by Memphis for Pharmaceutical and Chemical Industries) and stored in manufacturer's recommended conditions in a dry, cool environment for 1-16 weeks (depending on the date of recruitment) or placebo which is 1 ml saline injection. Syringes were labeled with a unique ID number and given by the blinded doctors choosing the next syringe with a randomization code. (only office secretary aware of randomization codes).
Study: NCT00439400
Drug: doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00439400
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02698501
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 doses in total, 4-week intervals), administered intravenously
Study: NCT03348904
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo for epacadostat administered orally twice daily.
Study: NCT03003676
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pre-treatment
Study: NCT03732638
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet to match rimegepant tablet EOD
Study: NCT00268749
Drug: glycine
Normalized name: Glycine
DrugBank: Glycine (DB00145)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.8 g/kg/day
Study: NCT00786916
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: A blood pressure cuff is placed with its distal-most margin 10 cm proximal to the intravenous catheter insertion site and is inflated to 40 mmHg of pressure greater than the patient's pre-procedure systolic blood pressure. Subjects will receive saline placebo IV (Group A) prior to initiating propofol infusion. Five minutes after administration of the study agent, tourniquet pressure is released and propofol infusion will be immediately initiated.
Study: NCT00058890
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01332305
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo orally once daily
Study: NCT02322606
Drug: TAK-137 5 mg tablet, TAK-137 placebo tablet
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02322606
Drug: TAK-137 5 mg tablet, TAK-137 placebo tablet or TAK-137 0.5 mg tablet, TAK-137 placebo tablet
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02322606
Drug: TAK-137 5mg tablet, TAK-137 placebo tablet
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00572572
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be randomized to receive placebo on days 3-7 on either cycle 1 or cycle 2.
Study: NCT00816634
Drug: Capecitabine plus cisplatin(XP) versus capecitabine plus paclitaxel(XT)
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3.2 Overview of Study Design This study is a prospective, randomized, phase II study comparing response rate between patients with XP chemotherapy versus XG chemotherapy for patients with metastatic squamous cell carcinoma.~Chemotherapy regimen (XP):~D1- D14 Capecitabine 1000 mg/m2 bid p.o. D1 Cisplatin 75 mg/m2 + NS 150mL MIV over 1hr every 3 weeks~Chemotherapy regimen (XT):~D1- D14 Capecitabine 1000 mg/m2 bid p.o. D1, D8 Genexol (Paclitaxel) 80 mg/m2 + D5W 500mL MIV over 3hrs every 3 weeks
Study: NCT00081588
Drug: TMC114
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600/100 mg tablets of TMC114/rtv BID for 144 weeks or until commercial available
Study: NCT01881451
Drug: 18F-EF5 PET/CT scan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will undergo an investigations 18F-EF5 PET/CT scan.
Study: NCT04327934
Drug: GnRH antagonist + MethylTESTOSTERone 5 MG
Normalized name: Methyltestosterone
DrugBank: Methyltestosterone (DB06710)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist + MethylTESTOSTERone 5 MG up to 5 days.
Study: NCT04153409
Drug: LAT8881
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two 30 mg capsules of LAT8881
Study: NCT04153409
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two capsules of placebo
Study: NCT03713619
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 300mg every 2 or every 4 weeks
Study: NCT01850160
Drug: GROUP A: Valsartan plus Chlorthalidone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of Valsartan plus Chlorthalidone: Valsartan 80 mg / Chlorthalidone 12,5 mg. Once daily during 12 weeks. If the goals of blood Pressure are uncontrolled at week 6, the dose will be increase to Valsartan 160 mg / Chlorthalidone 25 mg once daily.
Study: NCT01678976
Drug: BIA 2-093
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets containing BIA 2-093 in doses of 300 and 600 mg
Study: NCT01678976
Drug: Oxcarbazepine
Normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets containing 300 mg and 600 mg of Trileptal®
Study: NCT01711242
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01850160
Drug: GROUP C: Chlorthalidone
Approvals — FDA: no, EMA: no, PMDA: no
Description: GROUP C: Treatment monotherapy: Chlorthalidone 12,5 mg once daily during 12 weeks. If the goals of blood pressure are uncontrolled at week 6, the dose will be increase to Chlorthalidone 25 mg once daily.
Study: NCT01490060
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg/m\^2/day IV continuous infusion for 72 hours on days 1, 2, and 3, completing infusion on day 4 (total dose: 75 mg/m\^2) as part of AI Chemotherapy.
Study: NCT04289649
Drug: K-924 LD
Normalized name: K
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pitavastatin 2 mg / Ezetimibe 10 mg tables
Study: NCT04289649
Drug: K-924 HD
Normalized name: K
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pitavastatin 4 mg / Ezetimibe 10 mg tables
Study: NCT04289649
Drug: K-924 LD Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pitavastain 2 mg
Study: NCT04289649
Drug: K-924 HD Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pitavastain 4 mg
Study: NCT02838121
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: No IV aclasta
Study: NCT02268773
Drug: Asasantin®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02268773
Drug: Acetylsalicylic acid low dose
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02268773
Drug: Acetylsalicylic acid high dose
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00383435
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo MDI twice a day for 26 weeks
Study: NCT01063010
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered intravenously for 90 minutes (+ 15 minutes)
Study: NCT04574999
Drug: Estriol
Normalized name: Estriol
DrugBank: Estriol (DB04573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel for vaginal application
Study: NCT00770848
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02464969
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unfractionated heparin, low molecular weight heparin, and/or a vitamin K antagonist. For subjects under 2 years of age, standard of care will be limited to unfractionated heparin or low molecular weight heparin.
Study: NCT02799082
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical treatment for photodynamic therapy combining vehicle application and subsequent illumination with broad or narrow spectrum light sources (after 3 h of drug incubation).
Study: NCT02181231
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will remain on venlafaxine XR and be randomized to receive either placebo or buprenorphine for 8 weeks. at the end of the 8 weeks those who did not receive buprenorphine will be offered the opportunity to try it.
Study: NCT01713595
Drug: Hypertonic Saline Aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single 5ml dose of 7% Saline aerosol
Study: NCT01175226
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice daily
Study: NCT00835406
Drug: Fosamax® Tablets 70mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 70 mg, single dose fasting
Study: NCT00499889
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5 mg/m2 on days 1, 3, 6 and 11.
Study: NCT01769794
Drug: Western therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical cooling paste or warm bathing, vitamin B, vitamin C. On the basis of the attending physician's judgment, participants were allowed to use Ibuprofen suspension if their body temperature was greater than 38.5℃. Likewise, the need for antibiotics was determined by the attending physicians. The use of acetaminophen or antibiotics was recorded on the case record form
Study: NCT01769794
Drug: JET
Normalized name: Saljet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4g/tablet, One tablet each time (Taken after dissolved in 50ml boiled water, 3 times daily if body temperature≥38.5℃)
Study: NCT01769794
Drug: Placebo(for JET)
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebos prepared identical in color, taste and consistency to the JET (supplied by Zhongshenghaitian Pharmaceutical, Tianjin, China)
Study: NCT00851175
Drug: rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 7 day treatment with rosuvastatin 1dd 20mg
Study: NCT00851175
Drug: caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intra-arterial (brachial artery of non dominant arm) administration of caffeine(90 ug/min/100ml forearm volume)for approximately 60 minutes
Study: NCT01438190
Drug: Placebo, gonadotropins in step-up regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cps, two cps daily. Gonadotropins 75IU f, step-up regimen, starting dose of 75 IU daily.
Study: NCT02369133
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02261116
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02752048
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 group: Placebo group. Oral administration for 24 weeks, BID after meal
Study: NCT02605590
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03110159
Drug: Levulan® Kerastick®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levulan® Kerastick® for Topical Solution will be applied to a designated area for 3 hours without occlusion prior to illumination with blue light
Study: NCT03110159
Drug: BLU-U Blue Light Photodynamic Therapy
Normalized name: Blu-Kote
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 hours after Levulan® Kerastick® for Topical Solution is applied blue light illumination of designated area will be performed using the standard FDA approved treatment time of 16 minutes 40 seconds.
Study: NCT06038682
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heparin will be administered to the study subjects in this group in order to achieve anticoagulation.
Study: NCT00132769
Drug: Comparator: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to MK-0873 1.25 mg twice daily for 12 weeks
Study: NCT04394416
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01108744
Drug: hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% hypertonic saline, dosed by ideal patient weight
Study: NCT03128749
Drug: Treatment as Usual
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: The psychiatric referee will follow OCD guidelines modifying or potentiating drug treatments if needed.
Study: NCT01802411
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02520245
Drug: REGN2810
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive REGN2810 by intravenous (IV) infusion
Study: NCT01956305
Drug: DS-7309
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: DS-7309 powder in bottle
Study: NCT01956305
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo to match DS-7309 powder in bottle
Study: NCT04222283
Drug: BIKTARVY 50Mg-200Mg-25Mg Tablet
Normalized name: Biktarvy 50mg-200mg-25mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: At BSL all the participants will be switched from a booster containing regimen (ritonavir or cobicistat) to TAF/FTC/BIC (BIKTARVY).
Study: NCT00806221
Drug: emollient (Cetaphil cream)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetaphil cream applied daily from birth
Study: NCT03856229
Drug: Conventional steroid regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive the conventional steroid regimen with prednisolone or equivalent (with methylprednisolone): Day 1 to 5: 40 mg orally every 12 h; Day 6 to 10: 40 orally every 24 hours; and Day 11 to 21: 20 mg orally every 24 h.
Study: NCT03856229
Drug: Shortened steroid regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Subjects with Moderate PCP. Prednisolone (or equivalent with methylprednisolone) 40 mg orally every 12 h (Day 1 to 5);40 mg orally every 24 hours (Day 6 to 8).~* Subjects with severe PCP. Prednisolone (or equivalent with methylprednisolone) 40 mg orally every 12 h (Day 1 to 5),40 mg orally every 24 hours (Day 6 to 10); and 20 mg orally every 24 h (Day 11 to 14).
Study: NCT03265405
Drug: Low dose prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An initial dose of 20 mg/day will be administered for 8 weeks, followed by 15 mg/day for 8 weeks, 10 mg/day for 4 weeks, and 5 mg/day for 4 weeks, after which the drug will be tapered over 2 weeks and discontinued.
Study: NCT03265405
Drug: Medium dose prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An initial dose of 40 mg/day will be administered for 4 weeks, followed by 30 mg/day for 4 weeks, 20 mg/day for 4 weeks, 15 mg/day for 4 weeks, 10 mg/day for 4 weeks, and 5 mg/day for 4 weeks, after which the drug will be tapered over 2 weeks and discontinued.
Study: NCT01343706
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for oral administration
Study: NCT01343706
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate release solid oral dosage (film-coated tablet)
Study: NCT03285477
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle Ointment was used in participants with Clinically typical AK on the face or scalp.
Study: NCT03285477
Drug: KX2-391 Ointment 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: The experimental drug, KX2-391 Ointment 1% was used in participants with Clinically typical AK on the face or scalp.
Study: NCT01590641
Drug: Single Ascending Dose (SAD) Cohorts GS-9620
Approvals — FDA: no, EMA: no, PMDA: no
Description: This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Single Ascending Dose (SAD) Cohorts will receive a single dose of GS-9620.
Study: NCT01590641
Drug: Multiple Ascending Dose (MAD) Cohorts
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Multiple Ascending Dose (MAD) Cohorts will receive GS-9620 once weekly for two weeks (QW x 2 doses)
Study: NCT01693445
Drug: OIS (Oxaliplatin, Irinotecan, S-1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose level 1 treatment will be delivered as a 2-week cycle as bellows;~1. Oxaliplatin 85 mg/m²IV on day 1~2. Irinotecan 120 mg/m² IV on day 1~3. S-1 60 mg/m2/day PO on day 1-7~Dose escalation will be continued until more than one-third of the patients in a given cohort show dose limiting toxicities (DLT) during treatment cycle 1. If at least 2 patients are observed to have DLT, this dose level is defined as the maximum tolerated dose (MTD). If exactly 1 of the 3 patients treated show DLT, 3 additional patients are treated at the current dose level.
Study: NCT02103686
Drug: Experimental drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: sustained release formulation of pregabalin
Study: NCT00221364
Drug: Mass treatment with oral azithromycin to an entire village
Normalized name: Aldex AN
DrugBank: Doxylamine (DB00366)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04781075
Drug: Exparel Injectable Product
Normalized name: Exparel Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given at the beginning of the surgery for post-operative pain management
Study: NCT03124459
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant fusion protein or buffer solution
Study: NCT00317044
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice daily
Study: NCT00430118
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00430118
Drug: mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00430118
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00270894
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: cyclophosphamide (600 mg/m\^2) every 2 weeks for 4 cycles
Study: NCT03933943
Drug: LY3361237
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT03933943
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT01070329
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received placebo QD, po for 8 weeks, followed by placebo QD, po during the 2-week taper phase.
Study: NCT02154646
Drug: LY2157299
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT03576144
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple rising inhaled doses
Study: NCT02318095
Drug: Adjuvant chemotheapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy may be given after surgery at the clinical discretion of the medical oncologist
Study: NCT02071940
Drug: PLX3397
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLX3397 capsules 1000mg/day as monotherapy